Drugs / APSMNF 2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07516561 | Jul 2026 → Aug 2029 expected | androgenetic alopecia | Apsen Farmaceutica S.A. | Not yet recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | APSMNF 2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07516561 ↗ |